
Kevin is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Kevin is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.